# A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

> **NCT07158242** · PHASE3 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 100 (estimated)

## Conditions studied

- Moderately to Severely Active Ulcerative Colitis

## Interventions

- **DRUG:** Afimkibart

## Key facts

- **NCT ID:** NCT07158242
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2030-03-31
- **Final completion:** 2031-03-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07158242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07158242, "A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07158242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*